Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported fourth quarter and full year 2025 financial results and recent portfolio and business updates. As of December 31, 2025, Alector’s cas
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Alector (ALEC) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALEC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sellMarketBeat
- Alector to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary EndpointPR Newswire
- Alector (NASDAQ:ALEC) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
ALEC
Earnings
- 2/25/26 - Beat
ALEC
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 144
- 3/3/26 - Form 4
- ALEC's page on the SEC website